FR2941239B1 - METHOD FOR DETERMINING THE SUSCEPTIBILITY TO CONTRACT NOSOCOMIAL INFECTION IN A PATIENT WITH AN INFLAMMATORY SYSTEMIC RESPONSE ASSOCIATED WITH OR NOT ASSOCIATED WITH INFECTION - Google Patents

METHOD FOR DETERMINING THE SUSCEPTIBILITY TO CONTRACT NOSOCOMIAL INFECTION IN A PATIENT WITH AN INFLAMMATORY SYSTEMIC RESPONSE ASSOCIATED WITH OR NOT ASSOCIATED WITH INFECTION

Info

Publication number
FR2941239B1
FR2941239B1 FR0950305A FR0950305A FR2941239B1 FR 2941239 B1 FR2941239 B1 FR 2941239B1 FR 0950305 A FR0950305 A FR 0950305A FR 0950305 A FR0950305 A FR 0950305A FR 2941239 B1 FR2941239 B1 FR 2941239B1
Authority
FR
France
Prior art keywords
infection
patient
determining
inflammatory response
systemic inflammatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR0950305A
Other languages
French (fr)
Other versions
FR2941239A1 (en
Inventor
Marie Angelique Cazalis
Alain Lepape
Guillaume Monneret
Bruno Mougin
Alexandre Pachot
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomerieux SA
Hospices Civils de Lyon HCL
Original Assignee
Biomerieux SA
Hospices Civils de Lyon HCL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0950305A priority Critical patent/FR2941239B1/en
Application filed by Biomerieux SA, Hospices Civils de Lyon HCL filed Critical Biomerieux SA
Priority to RU2011134644/10A priority patent/RU2525707C2/en
Priority to PCT/FR2010/050070 priority patent/WO2010082004A1/en
Priority to ES10707312.4T priority patent/ES2556771T3/en
Priority to EP10707312.4A priority patent/EP2379752B1/en
Priority to KR1020187005733A priority patent/KR20180026561A/en
Priority to KR1020117019336A priority patent/KR101834993B1/en
Priority to CN201080004721.XA priority patent/CN102301008B/en
Priority to MX2011007624A priority patent/MX2011007624A/en
Priority to US13/140,678 priority patent/US11299768B2/en
Priority to BRPI1006850A priority patent/BRPI1006850B8/en
Priority to CN201410101355.XA priority patent/CN103923980B/en
Priority to JP2011545785A priority patent/JP5832903B2/en
Publication of FR2941239A1 publication Critical patent/FR2941239A1/en
Application granted granted Critical
Publication of FR2941239B1 publication Critical patent/FR2941239B1/en
Priority to RU2014122607A priority patent/RU2663724C2/en
Priority to JP2015113078A priority patent/JP6254975B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Determining susceptibility for contracting nosocomial infection in a patient having a systemic inflammatory response (non)associated with an infection, comprises collecting a biological sample from the patient and extracting biological material from biological sample; taking at least one specific reagent from an expression product of the target gene S100A9; and determining the expression of the target gene S100A9. Independent claims are included for: (1) establishing an early prognosis of survival in a patient having a systemic inflammatory response (non)associated with infection, or for determining the etiology of a systemic inflammatory response (non)associated with infection in patient, comprising (a) collecting biological sample from the patient and extracting from biological material from the biological sample, (b) collecting at least one reagent specific for an expression product of the target gene S100A9 and (c) determining the expression of the S100A9 target gene; (2) a first kit for determining susceptibility in contracting nosocomial infection in a patient having a systemic inflammatory response (non)associated with an infection comprising one reagent specific for S100A9 gene expression product; (3) use of at least one reagent for determining, in vitro, the susceptibility for contracting a nosocomial infection in a patient having systemic inflammatory response (non)associated with an infection; (4) a second kit for establishing an early prognosis for survival in a patient having a systemic inflammatory response (non)associated with an infection comprising at least one reagent specific for an expression product of S100A9 gene; and (5) use of at least one reagent for establishing, in vitro, a prognosis for survival in a patient having a systemic inflammatory response (non)associated with an infection.
FR0950305A 2009-01-19 2009-01-19 METHOD FOR DETERMINING THE SUSCEPTIBILITY TO CONTRACT NOSOCOMIAL INFECTION IN A PATIENT WITH AN INFLAMMATORY SYSTEMIC RESPONSE ASSOCIATED WITH OR NOT ASSOCIATED WITH INFECTION Active FR2941239B1 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
FR0950305A FR2941239B1 (en) 2009-01-19 2009-01-19 METHOD FOR DETERMINING THE SUSCEPTIBILITY TO CONTRACT NOSOCOMIAL INFECTION IN A PATIENT WITH AN INFLAMMATORY SYSTEMIC RESPONSE ASSOCIATED WITH OR NOT ASSOCIATED WITH INFECTION
BRPI1006850A BRPI1006850B8 (en) 2009-01-19 2010-01-18 process to determine susceptibility to contract nosocomial infection
ES10707312.4T ES2556771T3 (en) 2009-01-19 2010-01-18 Procedures to determine the susceptibility of contracting a nosocomial infection in a patient and to establish a prognosis of evolution of a septic syndrome
EP10707312.4A EP2379752B1 (en) 2009-01-19 2010-01-18 Methods for determining the susceptibility of a subject to contract a nosocomial infection and for establishing a prognose of evolution of septic syndrome
KR1020187005733A KR20180026561A (en) 2009-01-19 2010-01-18 Methods for determining the likelihood of a patient contracting a nosocomial infection and for determining the prognosis of the course of a septic syndrome
KR1020117019336A KR101834993B1 (en) 2009-01-19 2010-01-18 Methods for determining the likelihood of a patient contracting a nosocomial infection and for determining the prognosis of the course of a septic syndrome
CN201080004721.XA CN102301008B (en) 2009-01-19 2010-01-18 Methods for determining the likelihood of a patient contracting a nosocomial infection and for determining the prognosis of the course of a septic syndrome
MX2011007624A MX2011007624A (en) 2009-01-19 2010-01-18 Methods for determining the likelihood of a patient contracting a nosocomial infection and for determining the prognosis of the course of a septic syndrome.
RU2011134644/10A RU2525707C2 (en) 2009-01-19 2010-01-18 Methods for patient's response to hospital infection test and forecasting of developing sepsis syndrome
PCT/FR2010/050070 WO2010082004A1 (en) 2009-01-19 2010-01-18 Methods for determining the likelihood of a patient contracting a nosocomial infection and for determining the prognosis of the course of a septic syndrome
CN201410101355.XA CN103923980B (en) 2009-01-19 2010-01-18 Methods for determining the likelihood of a patient contracting a nosocomial infection and for determining the prognosis of the course of a septic syndrome
JP2011545785A JP5832903B2 (en) 2009-01-19 2010-01-18 A method to determine the susceptibility of patients with nosocomial infection and establish the prognosis of the progression of sepsis syndrome
US13/140,678 US11299768B2 (en) 2009-01-19 2010-01-18 Methods for determining a patient's susceptibility of contracting a nosocomial infection and for establishing a prognosis of the progression of septic syndrome
RU2014122607A RU2663724C2 (en) 2009-01-19 2014-06-03 Methods for determining patient's susceptibility to nosocomial infection and predicting development of a septic syndrome
JP2015113078A JP6254975B2 (en) 2009-01-19 2015-06-03 A method to determine the susceptibility of patients with nosocomial infection and establish the prognosis of the progression of sepsis syndrome

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0950305A FR2941239B1 (en) 2009-01-19 2009-01-19 METHOD FOR DETERMINING THE SUSCEPTIBILITY TO CONTRACT NOSOCOMIAL INFECTION IN A PATIENT WITH AN INFLAMMATORY SYSTEMIC RESPONSE ASSOCIATED WITH OR NOT ASSOCIATED WITH INFECTION

Publications (2)

Publication Number Publication Date
FR2941239A1 FR2941239A1 (en) 2010-07-23
FR2941239B1 true FR2941239B1 (en) 2013-11-15

Family

ID=40674226

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0950305A Active FR2941239B1 (en) 2009-01-19 2009-01-19 METHOD FOR DETERMINING THE SUSCEPTIBILITY TO CONTRACT NOSOCOMIAL INFECTION IN A PATIENT WITH AN INFLAMMATORY SYSTEMIC RESPONSE ASSOCIATED WITH OR NOT ASSOCIATED WITH INFECTION

Country Status (1)

Country Link
FR (1) FR2941239B1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3101358A1 (en) * 2019-09-27 2021-04-02 Bioaster Method for determining the risk of occurrence of an infection associated with care in a patient
FR3125300A1 (en) * 2021-07-19 2023-01-20 Biomerieux USE OF THE TORQUE TENO VIRUS (TTV) AS MARKERS TO DETERMINE THE RISK OF COMPLICATION IN A PATIENT ADMITTED TO A HEALTHCARE ESTABLISHMENT

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003212246A1 (en) * 2002-02-15 2003-09-04 Johannes Roth Method for diagnosis of inflammatory diseases using mrp8/mrp14
DE10324997A1 (en) * 2003-06-03 2004-12-23 Switch Biotech Ag Mrp8 / Mrp14 inhibitors and their use for the prevention and / or treatment of hypertrophic scars and keloids

Also Published As

Publication number Publication date
FR2941239A1 (en) 2010-07-23

Similar Documents

Publication Publication Date Title
Wang et al. Atherosclerosis-related circulating miRNAs as novel and sensitive predictors for acute myocardial infarction
JP2017530695A5 (en)
EA201170933A1 (en) ANALYSIS OF NUCLEIC ACIDS OBTAINED FROM SINGLE CELLS
WO2012112970A3 (en) Methods and compositions for detecting genetic material
JP2014525584A5 (en)
RU2014122607A (en) METHODS FOR DETERMINING A PATIENT'S SUSCEPTIBILITY TO IN-HOSPITAL INFECTION AND FORMING A FORECAST OF SEPTIC SYNDROME DEVELOPMENT
ES2530979T3 (en) Detection of nucleic acids and proteins
ATE491809T1 (en) AMPLIFICATION OF DNA FRAGMENTS
EP1988178A3 (en) Nucleotide primer set and nucleotide probe for detecting genotype of serum amyloid A1(SAA1)
BR112019000709A2 (en) system for assessing an antibiotic-treatable condition against a user and method for assessing an antibiotic-associated condition against a first user
WO2019074615A3 (en) In vitro methods for skin therapeutic compound discovery using skin age biomarkers
WO2013166444A3 (en) Biomarker analysis using scodaphoresis
WO2018195452A3 (en) Fluid-tight flow system to isolate biomarkers from a liquid sample
EP2176432A4 (en) Method for detecting disease markers
EP3825416A3 (en) Gene expression profiles associated with sub-clinical kidney transplant rejection
WO2015077382A3 (en) Combined cytology and molecular testing for early detection of esophageal adenocarcinoma
NZ732886A (en) Amplification and detection of nucleic acids in a biological sample
FR2941239B1 (en) METHOD FOR DETERMINING THE SUSCEPTIBILITY TO CONTRACT NOSOCOMIAL INFECTION IN A PATIENT WITH AN INFLAMMATORY SYSTEMIC RESPONSE ASSOCIATED WITH OR NOT ASSOCIATED WITH INFECTION
JP2017521086A5 (en)
SG10201807867XA (en) Simultaneous detection of target protein and target nucleic acids in a single cell
FR2970975B1 (en) METHOD AND KIT FOR DETERMINING IN VITRO THE IMMUNE STATUS OF AN INDIVIDUAL
EA201491821A1 (en) MODIFIED oligonucleotides, including thiol functional groups, and their use for the detection of nucleic acids
EA201391408A1 (en) METHOD FOR FORECASTING MOVEMENT STYLE IN HORSES
SG11201811433TA (en) Mmp1 gene transcript for use as marker for diagnosis of ovarian cancer prognosis, and test method
WO2016051177A3 (en) Methods and kits

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 8

PLFP Fee payment

Year of fee payment: 9

PLFP Fee payment

Year of fee payment: 10

PLFP Fee payment

Year of fee payment: 12

PLFP Fee payment

Year of fee payment: 13

PLFP Fee payment

Year of fee payment: 14

PLFP Fee payment

Year of fee payment: 15